Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)

INTRODUCTION: We tested the hypothesis that dipeptidyl peptidase-4 (DPP-4) inhibitors are effective in preserving the β-cell function for long-term periods in patients with slowly progressive type 1 diabetes (SPIDDM) or latent autoimmune diabetes in adults (LADA). METHODS: In the present open-label,...

Descripción completa

Detalles Bibliográficos
Autores principales: Awata, Takuya, Shimada, Akira, Maruyama, Taro, Oikawa, Yoichi, Yasukawa, Nobuyuki, Kurihara, Susumu, Miyashita, Yumi, Hatano, Masako, Ikegami, Yuichi, Matsuda, Masafumi, Niwa, Masataka, Kazama, Youichiro, Tanaka, Shoichiro, Kobayashi, Tetsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630555/
https://www.ncbi.nlm.nih.gov/pubmed/28929327
http://dx.doi.org/10.1007/s13300-017-0299-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630555/
https://www.ncbi.nlm.nih.gov/pubmed/28929327
http://dx.doi.org/10.1007/s13300-017-0299-7

Ejemplares similares